1Knopp R H. drug treatment of lipiddisorders [J]. New Eng J Med, 1999, 341 (7) : 498.
2The medical letter, Inc. Choice of lipid- regulatingdrugs [ J ]. Meal Lettdrug Ther2001 , 43 (1105) : 43.
3Insua A , Massari F , Rodriguez J, et al . Fenofibrate and gemfibrozil for treatment of types Iia and Iib primary hyperlipoproteinmia : a randomizeddouble blind crossover study[J]. Endocr Pract , 2002 , 8 (2) : 96.
4Keating GM, Ormordd. Micronised fenofibrate : an updated review of its dinical efficacy in the management ofdyslipidaemia[J]. drugs , 2002 , 62 (13): 1909.
5Capuzzid M, Guyton J R , Morgan J M, et al. Efficacy and safety of an extended -release niacin (Niaspan) : a long term study [J]. Am J Cardiol , 1998, 82 (12A) : 74.
6Guyton J R , Goldberg A C , Kreisberg R A , et al . Effectiveness of once nightlydasing of extended - release niacin alone and in combination for hypereholesterolemia[J]. Am J Cardiol , 1998 , 82 (6) : 737.
7Dujovne C A , Ettinger M P , McNeer J F , et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia [J].Am J Cardiol , 2002 , 90 (10) : 1092.
8Insull WJ , Koren M, Davignon J , et al. Efficacy and short - term safety of a new ACAT inhibitor, avasimibe , on lipids , lipoproteins, and apolipoproteins , in patients with combied hyperlipidemia[J]. Atherosclerosis , 2001 , 157 (1) : 137.
